Regulatory & Policy

Affinia Therapeutics Secures FDA Fast Track Designation for BAG3 Dilated Cardiomyopathy Gene Therapy AFTX-201

Edited by Robert McTiernan··3 min read

Affinia Therapeutics, a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, announced that the U.S. Food and Drug Administration has granted FDA Fast Track designation for AFTX-201, an adeno-associated virus (AAV) gene therapy designed to deliver a full-length human BAG3 transgene, for the treatment of BAG3-associated dilated cardiomyopathy (DCM). AFTX-201 uses a proprietary engineered capsid that the company states achieves cardiac transduction at doses five- to ten-fold lower than those required by conventional AAV serotypes such as AAV9 or AAVrh74. The therapy is administered as a single intravenous infusion.

Fast Track designation provides procedural benefits intended to shorten development timelines. These include early and frequent communication with the FDA during clinical development, eligibility for rolling submission of the marketing application, and potential qualification for accelerated approval or priority review if subsequent criteria are met. Affinia has also received European Medicines Agency (EMA) Orphan Drug Designation for AFTX-201, which confers regulatory and financial incentives for development in rare disease populations.

Affinia's capsid engineering platform originated from academic research at Harvard University, specifically from the laboratory of Luk Vandenberghe, a co-founder of the company. The proprietary capsid technology was licensed from Harvard at the company's founding and further developed in-house. AFTX-201 itself was generated internally by Affinia. The company is evaluating AFTX-201 in the UPBEAT clinical trial (NCT07426419), a multicenter, single-arm, open-label Phase I/II study in adults aged 18 to 55 with genetically confirmed truncating BAG3 mutations and symptomatic DCM, defined as left ventricular ejection fraction below 45% and New York Heart Association Class II or III status. The trial includes a dose-exploration phase followed by dose expansion, with planned enrollment of 22 participants. The primary endpoint is the number of participants experiencing treatment-emergent adverse events and serious adverse events through 52 weeks. Secondary and exploratory endpoints include pharmacodynamic assessments and changes in cardiac function from baseline, including peak oxygen consumption measured by cardiopulmonary exercise testing. The FDA approved the Investigational New Drug (IND) application for AFTX-201 prior to the Fast Track designation. The trial's anticipated start date is March 2026, with primary completion projected for December 2028.

Research context

The AllSci BriefSystematic R&D and deal news. Daily.

BAG3-associated DCM is a rare, monogenic form of heart failure caused by loss-of-function mutations in the BAG3 gene, which encodes a co-chaperone protein involved in sarcomere maintenance and autophagy in cardiomyocytes. DCM is the leading cause of heart failure in younger populations and the most frequent indication for heart transplantation. No disease-modifying therapies have been approved for BAG3-associated DCM or any genetically defined DCM subtype. Current management relies on standard heart failure pharmacotherapy — including neurohormonal antagonists and device-based interventions — none of which address the underlying genetic defect.

A search of ClinicalTrials.gov and AllSci identified no other active or recruiting interventional trials with therapeutic molecules directed at BAG3. AFTX-201 appears to be the only clinical-stage molecule targeting this gene. A separate AAV9-based BAG3 gene therapy program, REN-001, was previously under development by Renovacor, which Rocket Pharmaceuticals acquired in 2023; however, no active clinical trial for that program was identified in current registry data. Preclinical work on anti-BAG3 monoclonal antibodies in pancreatic cancer has been reported by academic groups but has not advanced to clinical testing.

Affinia's approach differs from earlier AAV-based cardiac gene therapy efforts primarily through its engineered capsid, which the company claims enables therapeutic transduction of the heart at lower vector doses. Conventional programs using AAV9 or AAVrh74 require higher systemic doses to achieve cardiac expression, which has been associated with dose-dependent toxicities including hepatotoxicity and thrombotic microangiopathy in other AAV gene therapy contexts. Whether Affinia's lower-dose strategy translates into a differentiated safety profile in humans remains to be determined by the UPBEAT trial. Preclinical studies in an animal disease model, cited by the company, reported restoration of cardiac ejection fraction to wild-type levels and what Affinia described as an adequate safety margin for the clinical doses under exploration.

Spot something wrong? Report an issue with this article